Researchers evaluated a drug that represents a new class of anticoagulants known as Factor XI inhibitors for treating patients with atrial fibrillation as part of the AZALEA-TIMI 71 Study. The trial ...

Subcutaneous injection of abelacimab results in lower levels of free factor XI and significantly fewer bleeding even ...

Patients with atrial fibrillation are typically prescribed an anticoagulant, or blood thinner, to reduce the risk of stroke, but many may discontinue them or never receive a prescription due to ...

Cardiovascular management strategies are essential to individuals with chronic lymphocytic leukemia (CLL) or multiple myeloma (MM) undergoing active treatment, due to the high rate of atrial ...

The following is a summary of “Factors associated with the detection of atrial fibrillation in patients with embolic stroke ...

Patients with atrial fibrillation are typically prescribed an anticoagulant, or blood thinner, to reduce the risk of stroke, but many may discontinue them or never receive a prescription due to ...

Risk for bleeding events is significantly affected by DOAC score in patients with atrial fibrillation who have received TAVR.

Background Atrial fibrillation (AF) and acute myocardial infarction (AMI) share risk factors and are bidirectionally associated. Several studies found higher risks of outcomes in individuals with both ...

Already cleared in the US for use in soft tissue ablation, Pulse Biosciences is looking to add AF to CellFX’s indication list ...

MIAMI - Pulse Biosciences, Inc. (NASDAQ:PLSE), a biotech company with a market capitalization of $1.08 billion and an ...

The results will support the company’s application for expanded labeling of its popular Farapulse pulsed field ablation ...